{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:01:03Z","timestamp":1773921663618,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,6,15]],"date-time":"2012-06-15T00:00:00Z","timestamp":1339718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hemodialysis International"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic kidney disease associated mineral and bone disorders arise as a result of aberrant bone mineral metabolism in patients with advancing levels of renal dysfunction and end\u2010stage renal disease. One of the cornerstones of treatment is the use of phosphate\u2010binding agents. We describe the rationale and study design for a clinical trial to assess the safety and efficacy of ferric citrate as a phosphate binder. This trial is a three\u2010period, international, multicenter, randomized, controlled clinical trial to assess the safety and efficacy of ferric citrate as a phosphate binder, consisting of a 2\u2010week washout period, a 52\u2010week safety assessment period in which subjects are randomized to ferric citrate or active control, and a 4\u2010week efficacy assessment period in which subjects randomized to ferric citrate in the safety assessment period are randomized to ferric citrate or placebo. Eligible subjects include end\u2010stage renal disease patients who have been treated with thrice\u2010weekly hemodialysis or peritoneal dialysis for at least 3 months in dialysis clinics in the <jats:styled-content style=\"fixed-case\">U<\/jats:styled-content>nited <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>tates and <jats:styled-content style=\"fixed-case\">I<\/jats:styled-content>srael. Primary outcome measure will be the effect of ferric citrate vs. placebo on the change in serum phosphorus. Safety assessments will be performed by monitoring adverse events, concomitant medication use, and sequential blood chemistries (including iron parameters, phosphorus, and calcium). This three\u2010period trial will assess the efficacy of ferric citrate as a phosphate binder. If proven safe and efficacious, ferric citrate will likely provide an additional phosphate binder to treat chronic kidney disease associated mineral and bone disorders.<\/jats:p>","DOI":"10.1111\/j.1542-4758.2012.00711.x","type":"journal-article","created":{"date-parts":[[2012,6,15]],"date-time":"2012-06-15T14:41:54Z","timestamp":1339771314000},"page":"67-74","source":"Crossref","is-referenced-by-count":18,"title":["Rationale and study design of a three\u2010period, 58\u2010week trial of ferric citrate as a phosphate binder in patients with <scp>ESRD<\/scp> on dialysis"],"prefix":"10.1111","volume":"17","author":[{"given":"Kausik","family":"Umanath","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension Henry Ford Hospital  Detroit MI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Sika","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension Vanderbilt University Medical Center  Nashville TN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Niecestro","sequence":"additional","affiliation":[{"name":"Keryx Biopharmaceuticals, Inc  New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Connelly","sequence":"additional","affiliation":[{"name":"Keryx Biopharmaceuticals, Inc  New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Schulman","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension Vanderbilt University Medical Center  Nashville TN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Koury","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Vanderbilt University Medical Center  Nashville TN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia B.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension Vanderbilt University Medical Center  Nashville TN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie P.","family":"Dwyer","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension Vanderbilt University Medical Center  Nashville TN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Collaborative Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,6,15]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.07304.x"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000133041.27682.A2"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000083712"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1042\/cs0390693"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1973.39"},{"key":"e_1_2_9_7_1","first-page":"425","article-title":"The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure","volume":"30","author":"Clarkson EM","year":"1966","journal-title":"Clin Sci"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(97)90352-8"},{"key":"e_1_2_9_9_1","first-page":"27","article-title":"The effect of a large intake of calcium citrate in normal subjects and patients with chronic renal failure","volume":"26","author":"McDonald SJ","year":"1964","journal-title":"Clin Sci"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01580407"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2006.02.003"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00753.x"},{"key":"e_1_2_9_13_1","first-page":"164","article-title":"Sevelamer reduces the efficacy of many other drugs","volume":"18","year":"2009","journal-title":"Prescrire Int"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2003.08.027"},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1681\/ASN.V1061274","article-title":"New phosphate binding agents: Ferric compounds","volume":"10","author":"Hsu CH","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.2.265"},{"key":"e_1_2_9_17_1","unstructured":"SikaM KouryM SmithM et\u2009al.Evaluation of ferric citrate as a phosphate binder in dialysis patients requiring high doses of phosphate binders. ASN Renal Week 2009. San Diego California 2009; TH\u2010PO361."},{"key":"e_1_2_9_18_1","unstructured":"SikaM SinsakulMV NiecestroRM ChiangS.Prolonged use of Ferric Citrate (FC) as a phosphate binder reduces IV iron use in Pts with ESRD. ASN Renal Week 2010. Denver Colorado 2010; SA\u2010PO2946."},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(03)00111-2"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05980809"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(97)90009-3"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.5414\/CNP65191"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(03)00554-7"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.00240.x"},{"key":"e_1_2_9_25_1","first-page":"S174","article-title":"Calcium and phosphate balance in dialysis patients","volume":"41","author":"Winchester JF","year":"1993","journal-title":"Kidney Int Suppl"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002617"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(04)00936-9"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00010505"},{"key":"e_1_2_9_29_1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/clinchem\/32.3.539","article-title":"Dietary citric acid enhances absorption of aluminum in antacids","volume":"32","author":"Slanina P","year":"1986","journal-title":"Clin Chem"}],"container-title":["Hemodialysis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1542-4758.2012.00711.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1542-4758.2012.00711.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T21:06:01Z","timestamp":1700600761000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1542-4758.2012.00711.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,15]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1111\/j.1542-4758.2012.00711.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1542-4758.2012.00711.x","archive":["Portico"],"relation":{},"ISSN":["1492-7535","1542-4758"],"issn-type":[{"value":"1492-7535","type":"print"},{"value":"1542-4758","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,15]]}}}